Immuron IMRN
NASDAQ IMRN
$0.97 +0.02 (+2.18%)
As of: Oct 23, 2026 · 1:52 PM EDT

Immuron (IMRN) Return on Sales [ROS] (2023 - 2024)

Updated

Immuron (IMRN) posted Return on Sales [ROS] of -51.98% for FY2026 (year ended Aug 28, 2026), up 21.88 percentage points from -73.85% in FY2025.

Analysis

Immuron (IMRN) Return on Sales [ROS] (2023 - 2024) Analysis & Trends

Since FY2015, Immuron has reported Return on Sales [ROS] for 12 fiscal years.

  • Annual Return on Sales [ROS] shows a five-year change of +5696.50 percentage points (FY2021 to FY2026).
  • The FY2026 figure stands as the highest annual Return on Sales [ROS] since FY2016.
  • Business Quant data shows IMRN's Return on Sales [ROS] at -73.85% in FY2025, -118.32% in FY2024 (-32.57 pp), -85.76% in FY2023 (+237.31 pp) and -323.07% in FY2022 (+5425.42 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,129.96 Bn 1,098.54 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.65 Bn 555.51 Bn 17.30 Bn 24.35%
3 AbbVie 504.89 Bn 478.00 Bn 12.70 Bn 37.86%
4 Merck 358.50 Bn 312.87 Bn 12.21 Bn -3.52%
5 Novartis Ag 291.04 Bn 255.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.27 Bn 238.95 Bn 12.86 Bn 20.57%
7 Amgen 237.76 Bn 193.16 Bn 7.24 Bn 34.95%
8 Gilead Sciences 195.00 Bn 169.20 Bn 6.22 Bn -133.21%
9 Pfizer 171.37 Bn 118.02 Bn 10.94 Bn 28.37%
10 Immuron 7.20 Mn -9.94 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 9, 2024 -118.32%
Dec 31, 2023 -197.75%
API Access

Immuron Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=IMRN&period=max&api_key=YOUR_API_KEY